Strain Name:

STOCK Arrb2tm1Rjl/J

Stock Number:

011130

Order this mouse

Availability:

Repository- Live

These Arrb2 (arrestin, beta 2) knock-out mice show a significantly increased potentiation and prolongation of the analgesic effect of morphine, and may be useful in studies of pain and analgesia.

Description

Strain Information

Former Names B6.129-Arrb2tm1Rjl/J    (Changed: 15-JUL-13 )
Type Mutant Stock; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Mating SystemHeterozygote x Heterozygote         (Female x Male)   04-DEC-12
Specieslaboratory mouse
Generation?+pN1F1 (06-JUN-13)
Generation Definitions
 
Donating Investigator Robert Lefkowitz,   Duke University Medical Center

Description
Homozygous Arrb2 (arrestin, beta 2) targeted mutation mice show a significantly increased potentiation and prolongation of the analgesic effect of morphine, suggesting that μ opioid receptor desensitization is impaired. They lack expression of the gene as determined by immunoblot of brainstem, periaqueductal gray tissue, spleen, lung, and skin. These mice may be useful in studies of pain and analgesia.

Development
A targeting vector was designed to insert a neomycin resistance cassette and delete exon 2 of the beta-arrestin 2 gene Arrb2) on chromosome 11. This strain was created in a 129-derived embryonic stem cell line. Mutant mice were backcrossed to C57BL/6 for more than ten generations by the donating laboratory (see SNP results below) prior to sending males to The Jackson Laboratory Repository in 2012. Upon arrival, males were used to cryopreserve sperm. To establish the living mouse colony, an aliquot of the frozen sperm was used to fertilize C57BL/6J oocytes (Stock No. 000664).

A 32 SNP (single nucleotide polymorphism) panel analysis, with 27 markers covering all 19 chromosomes and the X chromosome, as well as 5 markers that distinguish between the C57BL/6J and C57BL/6N substrains, was performed on the living colony at The Jackson Laboratory Repository. This revealed 2 of 27 markers, one each on chromosomes 1 and 2, that were not fixed for C57BL/6 allele-type (e.g.: still segregating for 129 allele-type markers). In addition, 1 marker on chromosome 17 (~34 Mbp) was found to be segregating for a marker of unknown genetic contribution. These data suggest the mice may have been backcrossed to C57BL/6 for fewer generations than reported prior to arrival at The Jackson Laboratory.

Control Information

  Control
   Wild-type from the colony
   000664 C57BL/6J (approximate)
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Arrb2tm1Rjl allele
023852   B6.129X1-Arrb2tm1Rjl/J
View Strains carrying   Arrb2tm1Rjl     (1 strain)

Strains carrying other alleles of Arrb2
018608   B6N(Cg)-Arrb2tm1.1(KOMP)Vlcg/J
View Strains carrying other alleles of Arrb2     (1 strain)

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Arrb2tm1Rjl/Arrb2tm1Rjl

        involves: 129X1/SvJ * C57BL/6
  • immune system phenotype
  • abnormal circulating tumor necrosis factor level
    • there is a 3-fold increase in serum levels of TNF 1 hour after injection with LPS compared wild-type controls   (MGI Ref ID J:112607)
  • abnormal lymphocyte physiology
    • chemotaxic response of both T and B lymphocytes to CXCL12 is significantly reduced   (MGI Ref ID J:76872)
  • increased acute inflammation
    • mice have a heightened response to endotoxins including less survivability and increased pro-inflammatory cytokine production   (MGI Ref ID J:112607)
    • increased susceptibility to endotoxin shock
      • 89% of mice die within 12 hours of a LPS and D-galactosamine injection compared to 0% for wild-type mice   (MGI Ref ID J:112607)
      • the mice die of endotoxin shock   (MGI Ref ID J:112607)
  • increased circulating interleukin-6 level
    • there is a 2-fold increase in serum levels of IL-6 in mutant mice after LPS injection compared to wild-type controls   (MGI Ref ID J:112607)
  • increased interleukin-12b secretion
    • bone marrow derived macrophages produce 1.5-fold to 2-fold more IL12p40 in response to agonists to TLR-3, -4, -9, and CD40 compared to controls   (MGI Ref ID J:112607)
  • increased interleukin-6 secretion
    • there is a 2-fold increase in serum levels of IL-6 in mutant mice compared to wild-type controls   (MGI Ref ID J:112607)
  • increased tumor necrosis factor secretion
    • bone marrow derived macrophages produce 1.5-fold to 3-fold more TNF in response to agonists to TLR-3, -4, -9, and CD40 compared to controls   (MGI Ref ID J:112607)
  • homeostasis/metabolism phenotype
  • abnormal body temperature homeostasis
    • homozygotes exhibit no significant differences in basal body temperature relative to wild-type mice (36.8 0.1C vs 36.4 0.1C, respectively)   (MGI Ref ID J:59162)
    • however, homozygotes display a significantly increased and prolonged hypothermia in response to morphine treatment   (MGI Ref ID J:59162)
  • abnormal circulating tumor necrosis factor level
    • there is a 3-fold increase in serum levels of TNF 1 hour after injection with LPS compared wild-type controls   (MGI Ref ID J:112607)
  • increased circulating interleukin-6 level
    • there is a 2-fold increase in serum levels of IL-6 in mutant mice after LPS injection compared to wild-type controls   (MGI Ref ID J:112607)
  • behavior/neurological phenotype
  • increased chemically-elicited antinociception
    • homozygotes are viable and overtly normal with no significant differences in morphine metabolism or basal responses to the hot plate test relative to wild-type mice   (MGI Ref ID J:59162)
    • however, homozygotes exhibit enhanced and prolonged morphine-induced antinociception, as measured by hot-plate response latencies (56C), with significant analgesia noted at 4 hrs [% maximum possible effect = 31 0.4%] after s.c. morphine injection relative to wild-type mice in which analgesia of the same morphine dose (10 mg/kg) wanes after ~90 min   (MGI Ref ID J:59162)
    • enhanced morphine-induced antinociception is dose-dependent and completely reversed with the mu opioid receptor (OR) antagonist naloxone (2.5 mg/kg sc), suggesting impaired OR desensitization   (MGI Ref ID J:59162)
    • in addition, antinociceptive behaviors are correlated with enhanced OR-G-protein coupling in mutant hypothalamus, brainstem, periaqueductal gray tissues   (MGI Ref ID J:59162)
  • integument phenotype
  • increased chemically-elicited antinociception
    • homozygotes are viable and overtly normal with no significant differences in morphine metabolism or basal responses to the hot plate test relative to wild-type mice   (MGI Ref ID J:59162)
    • however, homozygotes exhibit enhanced and prolonged morphine-induced antinociception, as measured by hot-plate response latencies (56C), with significant analgesia noted at 4 hrs [% maximum possible effect = 31 0.4%] after s.c. morphine injection relative to wild-type mice in which analgesia of the same morphine dose (10 mg/kg) wanes after ~90 min   (MGI Ref ID J:59162)
    • enhanced morphine-induced antinociception is dose-dependent and completely reversed with the mu opioid receptor (OR) antagonist naloxone (2.5 mg/kg sc), suggesting impaired OR desensitization   (MGI Ref ID J:59162)
    • in addition, antinociceptive behaviors are correlated with enhanced OR-G-protein coupling in mutant hypothalamus, brainstem, periaqueductal gray tissues   (MGI Ref ID J:59162)
  • hematopoietic system phenotype
  • abnormal lymphocyte physiology
    • chemotaxic response of both T and B lymphocytes to CXCL12 is significantly reduced   (MGI Ref ID J:76872)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Neurobiology Research
Receptor Defects
      opiod

Sensorineural Research
Nociception

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Arrb2tm1Rjl
Allele Name targeted mutation 1, Robert J Lefkowitz
Allele Type Targeted (Null/Knockout)
Common Name(s) Arrb2-; betaarr2-; betarr2-KO;
Mutation Made By Robert Lefkowitz,   Duke University Medical Center
Strain of Origin129X1/SvJ
Gene Symbol and Name Arrb2, arrestin, beta 2
Chromosome 11
Gene Common Name(s) AI326910; ARB2; ARR2; AW122872; BARR2; BARRES; beta arr2; beta-arrestin-2; beta-arrestin2; expressed sequence AI326910; expressed sequence AW122872;
Molecular Note PGK-neomycin cassette replaced the entire second exon. This resulted in the deletion of amino acids 9-19. The absence of protein was demonstrated by immunoblotting of extracts from brainstem, periaqueductal gray tissue, spleen, lung, and skin. [MGI Ref ID J:59162]

Genotyping

Genotyping Information

Genotyping Protocols

Arrb2tm1Rjl,

Separated MCA


Arrb2tm1Rjl, Separated PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Bohn LM; Lefkowitz RJ; Gainetdinov RR; Peppel K; Caron MG; Lin FT. 1999. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286(5449):2495-8. [PubMed: 10617462]  [MGI Ref ID J:59162]

Additional References

Arrb2tm1Rjl related

Arttamangkul S; Quillinan N; Low MJ; von Zastrow M; Pintar J; Williams JT. 2008. Differential activation and trafficking of micro-opioid receptors in brain slices. Mol Pharmacol 74(4):972-9. [PubMed: 18612077]  [MGI Ref ID J:151536]

Beaulieu JM; Sotnikova TD; Marion S; Lefkowitz RJ; Gainetdinov RR; Caron MG. 2005. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122(2):261-73. [PubMed: 16051150]  [MGI Ref ID J:115106]

Bjork K; Rimondini R; Hansson AC; Terasmaa A; Hyytia P; Heilig M; Sommer WH. 2008. Modulation of voluntary ethanol consumption by beta-arrestin 2. FASEB J 22(7):2552-60. [PubMed: 18367649]  [MGI Ref ID J:138011]

Bohn LM; Gainetdinov RR; Lin FT; Lefkowitz RJ; Caron MG. 2000. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408(6813):720-3. [PubMed: 11130073]  [MGI Ref ID J:66098]

Bohn LM; Gainetdinov RR; Sotnikova TD; Medvedev IO; Lefkowitz RJ; Dykstra LA; Caron MG. 2003. Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci 23(32):10265-73. [PubMed: 14614085]  [MGI Ref ID J:86582]

Bohn LM; Lefkowitz RJ; Caron MG. 2002. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 22(23):10494-500. [PubMed: 12451149]  [MGI Ref ID J:80433]

Bonnans C; Flaceliere M; Grillet F; Dantec C; Desvignes JP; Pannequin J; Severac D; Dubois E; Bibeau F; Escriou V; Crespy P; Journot L; Hollande F; Joubert D. 2012. Essential requirement for beta-arrestin2 in mouse intestinal tumors with elevated Wnt signaling. Proc Natl Acad Sci U S A 109(8):3047-52. [PubMed: 22315403]  [MGI Ref ID J:182012]

Bouxsein ML; Pierroz DD; Glatt V; Goddard DS; Cavat F; Rizzoli R; Ferrari SL. 2005. beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J Bone Miner Res 20(4):635-43. [PubMed: 15765183]  [MGI Ref ID J:111276]

Bradaia A; Berton F; Ferrari S; Luscher C. 2005. beta-Arrestin2, interacting with phosphodiesterase 4, regulates synaptic release probability and presynaptic inhibition by opioids. Proc Natl Acad Sci U S A 102(8):3034-9. [PubMed: 15718284]  [MGI Ref ID J:96827]

Bryja V; Gradl D; Schambony A; Arenas E; Schulte G. 2007. beta-Arrestin is a necessary component of Wnt/beta-catenin signaling in vitro and in vivo. Proc Natl Acad Sci U S A 104(16):6690-5. [PubMed: 17426148]  [MGI Ref ID J:120936]

Chen W; Kirkbride KC; How T; Nelson CD; Mo J; Frederick JP; Wang XF; Lefkowitz RJ; Blobe GC. 2003. Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science 301(5638):1394-7. [PubMed: 12958365]  [MGI Ref ID J:125428]

Daigle TL; Wetsel WC; Caron MG. 2011. Opposite function of dopamine D1 and N-methyl-D-aspartate receptors in striatal cannabinoid-mediated signaling. Eur J Neurosci 34(9):1378-89. [PubMed: 22034973]  [MGI Ref ID J:183176]

Dang VC; Napier IA; Christie MJ. 2009. Two distinct mechanisms mediate acute micro-opioid receptor desensitization in native neurons. J Neurosci 29(10):3322-7. [PubMed: 19279269]  [MGI Ref ID J:147067]

David DJ; Samuels BA; Rainer Q; Wang JW; Marsteller D; Mendez I; Drew M; Craig DA; Guiard BP; Guilloux JP; Artymyshyn RP; Gardier AM; Gerald C; Antonijevic IA; Leonardo ED; Hen R. 2009. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62(4):479-93. [PubMed: 19477151]  [MGI Ref ID J:157357]

Fan H; Bitto A; Zingarelli B; Luttrell LM; Borg K; Halushka PV; Cook JA. 2010. Beta-arrestin 2 negatively regulates sepsis-induced inflammation. Immunology 130(3):344-51. [PubMed: 20465566]  [MGI Ref ID J:166405]

Fan H; Luttrell LM; Tempel GE; Senn JJ; Halushka PV; Cook JA. 2007. beta-Arrestins 1 and 2 differentially regulate LPS-induced signaling and pro-inflammatory gene expression. Mol Immunol 44(12):3092-9. [PubMed: 17418896]  [MGI Ref ID J:120965]

Fereshteh M; Ito T; Kovacs JJ; Zhao C; Kwon HY; Tornini V; Konuma T; Chen M; Lefkowitz RJ; Reya T. 2012. beta-Arrestin2 mediates the initiation and progression of myeloid leukemia. Proc Natl Acad Sci U S A 109(31):12532-7. [PubMed: 22773819]  [MGI Ref ID J:188541]

Fong AM; Premont RT; Richardson RM; Yu YR; Lefkowitz RJ; Patel DD. 2002. Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice. Proc Natl Acad Sci U S A 99(11):7478-83. [PubMed: 12032308]  [MGI Ref ID J:76872]

Gaffal E; Jakobs M; Glodde N; Schroder R; Kostenis E; Tuting T. 2014. beta-Arrestin 2 Inhibits Proinflammatory Chemokine Production and Attenuates Contact Allergic Inflammation in the Skin. J Invest Dermatol 134(8):2131-7. [PubMed: 24577407]  [MGI Ref ID J:212136]

Gesty-Palmer D; Flannery P; Yuan L; Corsino L; Spurney R; Lefkowitz RJ; Luttrell LM. 2009. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1(1):1ra1. [PubMed: 20368153]  [MGI Ref ID J:167888]

Grotegut CA; Feng L; Mao L; Heine RP; Murtha AP; Rockman HA. 2011. beta-Arrestin mediates oxytocin receptor signaling, which regulates uterine contractility and cellular migration. Am J Physiol Endocrinol Metab 300(3):E468-77. [PubMed: 21139074]  [MGI Ref ID J:172317]

Hack SP; Bagley EE; Chieng BC; Christie MJ. 2005. Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment. J Neurosci 25(12):3192-8. [PubMed: 15788776]  [MGI Ref ID J:98278]

Hara MR; Kovacs JJ; Whalen EJ; Rajagopal S; Strachan RT; Grant W; Towers AJ; Williams B; Lam CM; Xiao K; Shenoy SK; Gregory SG; Ahn S; Duckett DR; Lefkowitz RJ. 2011. A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Nature 477(7364):349-53. [PubMed: 21857681]  [MGI Ref ID J:176251]

Hollingsworth JW; Theriot BS; Li Z; Lawson BL; Sunday M; Schwartz DA; Walker JK. 2010. Both hematopoietic-derived and non-hematopoietic-derived {beta}-arrestin-2 regulates murine allergic airway disease. Am J Respir Cell Mol Biol 43(3):269-75. [PubMed: 19805483]  [MGI Ref ID J:177817]

Kim J; Zhang L; Peppel K; Wu JH; Zidar DA; Brian L; DeWire SM; Exum ST; Lefkowitz RJ; Freedman NJ. 2008. Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res 103(1):70-9. [PubMed: 18519945]  [MGI Ref ID J:151375]

Kim KS; Abraham D; Williams B; Violin JD; Mao L; Rockman HA. 2012. beta-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol 303(8):H1001-10. [PubMed: 22886417]  [MGI Ref ID J:191427]

Kohout TA; Lin FS; Perry SJ; Conner DA; Lefkowitz RJ. 2001. beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci U S A 98(4):1601-6. [PubMed: 11171997]  [MGI Ref ID J:67546]

Lattin JE; Greenwood KP; Daly NL; Kelly G; Zidar DA; Clark RJ; Thomas WG; Kellie S; Craik DJ; Hume DA; Sweet MJ. 2009. Beta-arrestin 2 is required for complement C1q expression in macrophages and constrains factor-independent survival. Mol Immunol 47(2-3):340-7. [PubMed: 19783052]  [MGI Ref ID J:155230]

Li D; D'Angelo L; Chavez M; Woulfe DS. 2011. Arrestin-2 Differentially Regulates PAR4 and ADP Receptor Signaling in Platelets. J Biol Chem 286(5):3805-14. [PubMed: 21106537]  [MGI Ref ID J:168743]

Li P; Cook JA; Gilkeson GS; Luttrell LM; Wang L; Borg KT; Halushka PV; Fan H. 2011. Increased expression of beta-arrestin 1 and 2 in murine models of rheumatoid arthritis: Isoform specific regulation of inflammation. Mol Immunol 49(1-2):64-74. [PubMed: 21855149]  [MGI Ref ID J:177193]

Li Y; Li H; Liu X; Bao G; Tao Y; Wu Z; Xia P; Wu C; Li B; Ma L. 2009. Regulation of amygdalar PKA by {beta}-arrestin-2/phosphodiesterase-4 complex is critical for fear conditioning. Proc Natl Acad Sci U S A :. [PubMed: 19955404]  [MGI Ref ID J:155523]

Lovgren AK; Kovacs JJ; Xie T; Potts EN; Li Y; Foster WM; Liang J; Meltzer EB; Jiang D; Lefkowitz RJ; Noble PW. 2011. {beta}-Arrestin Deficiency Protects Against Pulmonary Fibrosis in Mice and Prevents Fibroblast Invasion of Extracellular Matrix. Sci Transl Med 3(74):74ra23. [PubMed: 21411739]  [MGI Ref ID J:170989]

Luan B; Zhao J; Wu H; Duan B; Shu G; Wang X; Li D; Jia W; Kang J; Pei G. 2009. Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature 457(7233):1146-9. [PubMed: 19122674]  [MGI Ref ID J:145752]

McAlees JW; Sanders VM. 2009. Hematopoietic protein tyrosine phosphatase mediates beta2-adrenergic receptor-induced regulation of p38 mitogen-activated protein kinase in B lymphocytes. Mol Cell Biol 29(3):675-86. [PubMed: 19047375]  [MGI Ref ID J:145544]

Molteni R; Crespo CL; Feigelson S; Moser C; Fabbri M; Grabovsky V; Krombach F; Laudanna C; Alon R; Pardi R. 2009. Beta-arrestin 2 is required for the induction and strengthening of integrin-mediated leukocyte adhesion during CXCR2-driven extravasation. Blood 114(5):1073-82. [PubMed: 19429870]  [MGI Ref ID J:151172]

Moorman J; Zhang Y; Liu B; LeSage G; Chen Y; Stuart C; Prayther D; Yin D. 2009. HIV-1 gp120 primes lymphocytes for opioid-induced, beta-arrestin 2-dependent apoptosis. Biochim Biophys Acta 1793(8):1366-71. [PubMed: 19477204]  [MGI Ref ID J:153465]

Nichols HL; Saffeddine M; Theriot BS; Hegde A; Polley D; El-Mays T; Vliagoftis H; Hollenberg MD; Wilson EH; Walker JK; DeFea KA. 2012. beta-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway. Proc Natl Acad Sci U S A 109(41):16660-5. [PubMed: 23012429]  [MGI Ref ID J:190326]

Pi M; Oakley RH; Gesty-Palmer D; Cruickshank RD; Spurney RF; Luttrell LM; Quarles LD. 2005. Beta-arrestin- and G protein receptor kinase-mediated calcium-sensing receptor desensitization. Mol Endocrinol 19(4):1078-87. [PubMed: 15637145]  [MGI Ref ID J:97178]

Pierroz DD; Rufo A; Bianchi EN; Glatt V; Capulli M; Rucci N; Cavat F; Rizzoli R; Teti A; Bouxsein ML; Ferrari SL. 2009. Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J Bone Miner Res 24(5):775-84. [PubMed: 19113915]  [MGI Ref ID J:169515]

Pontrello CG; Sun MY; Lin A; Fiacco TA; DeFea KA; Ethell IM. 2012. Cofilin under control of beta-arrestin-2 in NMDA-dependent dendritic spine plasticity, long-term depression (LTD), and learning. Proc Natl Acad Sci U S A 109(7):E442-51. [PubMed: 22308427]  [MGI Ref ID J:182613]

Por ED; Bierbower SM; Berg KA; Gomez R; Akopian AN; Wetsel WC; Jeske NA. 2012. beta-Arrestin-2 desensitizes the transient receptor potential vanilloid 1 (TRPV1) channel. J Biol Chem 287(44):37552-63. [PubMed: 22952227]  [MGI Ref ID J:192132]

Raehal KM; Bohn LM. 2011. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 60(1):58-65. [PubMed: 20713067]  [MGI Ref ID J:178516]

Raghuwanshi SK; Nasser MW; Chen X; Strieter RM; Richardson RM. 2008. Depletion of beta-arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 180(8):5699-706. [PubMed: 18390755]  [MGI Ref ID J:134231]

Raghuwanshi SK; Smith N; Rivers EJ; Thomas AJ; Sutton N; Hu Y; Mukhopadhyay S; Chen XL; Leung T; Richardson RM. 2013. G protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression, and metastasis. J Immunol 190(10):5329-36. [PubMed: 23589623]  [MGI Ref ID J:202546]

Rajagopal K; Whalen EJ; Violin JD; Stiber JA; Rosenberg PB; Premont RT; Coffman TM; Rockman HA; Lefkowitz RJ. 2006. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A 103(44):16284-9. [PubMed: 17060617]  [MGI Ref ID J:115598]

Rakesh K; Yoo B; Kim IM; Salazar N; Kim KS; Rockman HA. 2010. beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal 3(125):ra46. [PubMed: 20530803]  [MGI Ref ID J:185409]

Ravier MA; Leduc M; Richard J; Linck N; Varrault A; Pirot N; Roussel MM; Bockaert J; Dalle S; Bertrand G. 2014. beta-Arrestin2 plays a key role in the modulation of the pancreatic beta cell mass in mice. Diabetologia 57(3):532-41. [PubMed: 24317793]  [MGI Ref ID J:208375]

Schmid CL; Raehal KM; Bohn LM. 2008. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A 105(3):1079-84. [PubMed: 18195357]  [MGI Ref ID J:131285]

Schmid CL; Streicher JM; Groer CE; Munro TA; Zhou L; Bohn LM. 2013. Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at kappa-opioid receptors in striatal neurons. J Biol Chem 288(31):22387-98. [PubMed: 23775075]  [MGI Ref ID J:201919]

Sharma D; Malik A; Lee E; Britton RA; Parameswaran N. 2013. Gene dosage-dependent negative regulatory role of beta-arrestin-2 in polymicrobial infection-induced inflammation. Infect Immun 81(8):3035-44. [PubMed: 23753627]  [MGI Ref ID J:199834]

Shi Y; Feng Y; Kang J; Liu C; Li Z; Li D; Cao W; Qiu J; Guo Z; Bi E; Zang L; Lu C; Zhang JZ; Pei G. 2007. Critical regulation of CD4(+) T cell survival and autoimmunity by beta-arrestin 1. Nat Immunol 8(8):817-24. [PubMed: 17618287]  [MGI Ref ID J:123410]

Su Y; Raghuwanshi SK; Yu Y; Nanney LB; Richardson RM; Richmond A. 2005. Altered CXCR2 signaling in beta-arrestin-2-deficient mouse models. J Immunol 175(8):5396-402. [PubMed: 16210646]  [MGI Ref ID J:119105]

Tilley DG; Nguyen AD; Rockman HA. 2010. Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor. Biochem Biophys Res Commun 396(4):921-6. [PubMed: 20460106]  [MGI Ref ID J:162434]

Trivedi DB; Loftin CD; Clark J; Myers P; DeGraff LM; Cheng J; Zeldin DC; Langenbach R. 2013. beta-Arrestin-2 deficiency attenuates abdominal aortic aneurysm formation in mice. Circ Res 112(9):1219-29. [PubMed: 23524589]  [MGI Ref ID J:213307]

Walker JK; Fong AM; Lawson BL; Savov JD; Patel DD; Schwartz DA; Lefkowitz RJ. 2003. Beta-arrestin-2 regulates the development of allergic asthma. J Clin Invest 112(4):566-74. [PubMed: 12925697]  [MGI Ref ID J:85157]

Walters RW; Shukla AK; Kovacs JJ; Violin JD; DeWire SM; Lam CM; Chen JR; Muehlbauer MJ; Whalen EJ; Lefkowitz RJ. 2009. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 119(5):1312-21. [PubMed: 19349687]  [MGI Ref ID J:149594]

Wang Y; Tang Y; Teng L; Wu Y; Zhao X; Pei G. 2006. Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 7(2):139-47. [PubMed: 16378096]  [MGI Ref ID J:112607]

Watari K; Nakaya M; Nishida M; Kim KM; Kurose H. 2013. beta-arrestin2 in infiltrated macrophages inhibits excessive inflammation after myocardial infarction. PLoS One 8(7):e68351. [PubMed: 23861891]  [MGI Ref ID J:204286]

Wu JH; Peppel K; Nelson CD; Lin FT; Kohout TA; Miller WE; Exum ST; Freedman NJ. 2003. The adaptor protein beta-arrestin2 enhances endocytosis of the low density lipoprotein receptor. J Biol Chem 278(45):44238-45. [PubMed: 12944399]  [MGI Ref ID J:86555]

Yan Y; Jiang W; Spinetti T; Tardivel A; Castillo R; Bourquin C; Guarda G; Tian Z; Tschopp J; Zhou R. 2013. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38(6):1154-63. [PubMed: 23809162]  [MGI Ref ID J:207575]

Zhang M; Liu X; Zhang Y; Zhao J. 2010. Loss of betaarrestin1 and betaarrestin2 contributes to pulmonary hypoplasia and neonatal lethality in mice. Dev Biol 339(2):407-17. [PubMed: 20060823]  [MGI Ref ID J:159121]

Zhang M; Teng H; Shi J; Zhang Y. 2011. Disruption of beta-arrestins blocks glucocorticoid receptor and severely retards lung and liver development in mice. Mech Dev 128(7-10):368-75. [PubMed: 21824517]  [MGI Ref ID J:178360]

Zhang M; Zhu Y; Mu K; Li L; Lu J; Zhao J; Huang X; Wang C; Jia W. 2013. Loss of beta-arrestin2 mediates pancreatic-islet dysfunction in mice. Biochem Biophys Res Commun 435(3):345-9. [PubMed: 23660189]  [MGI Ref ID J:202642]

Zhang Y; Liu C; Wei B; Pei G. 2013. Loss of beta-arrestin 2 exacerbates experimental autoimmune encephalomyelitis with reduced number of Foxp3+ CD4+ regulatory T cells. Immunology 140(4):430-40. [PubMed: 23859136]  [MGI Ref ID J:209555]

Zhuang LN; Hu WX; Xin SM; Zhao J; Pei G. 2011. Beta-arrestin-1 protein represses adipogenesis and inflammatory responses through its interaction with peroxisome proliferator-activated receptor-gamma (PPARgamma). J Biol Chem 286(32):28403-13. [PubMed: 21700709]  [MGI Ref ID J:175917]

Zhuang LN; Hu WX; Zhang ML; Xin SM; Jia WP; Zhao J; Pei G. 2011. {beta}-Arrestin-1 Protein Represses Diet-induced Obesity. J Biol Chem 286(32):28396-402. [PubMed: 21543334]  [MGI Ref ID J:175666]

Zoudilova M; Min J; Richards HL; Carter D; Huang T; DeFea KA. 2010. beta-Arrestins scaffold cofilin with chronophin to direct localized actin filament severing and membrane protrusions downstream of protease-activated receptor-2. J Biol Chem 285(19):14318-29. [PubMed: 20207744]  [MGI Ref ID J:162966]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX18

Colony Maintenance

Breeding & HusbandryWhen maintained as a live colony, homozygotes or heterozygotes may be bred.
Mating SystemHeterozygote x Heterozygote         (Female x Male)   04-DEC-12
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $232.00Female or MaleHeterozygous for Arrb2tm1Rjl  
$232.00Female or MaleHomozygous for Arrb2tm1Rjl  
Price per Pair (US dollars $)Pair Genotype
$464.00Homozygous for Arrb2tm1Rjl x Homozygous for Arrb2tm1Rjl  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $301.60Female or MaleHeterozygous for Arrb2tm1Rjl  
$301.60Female or MaleHomozygous for Arrb2tm1Rjl  
Price per Pair (US dollars $)Pair Genotype
$603.20Homozygous for Arrb2tm1Rjl x Homozygous for Arrb2tm1Rjl  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

  Control
   Wild-type from the colony
   000664 C57BL/6J (approximate)
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)